ENTRESTO® rapidly improves the heart’s structure and function11
Abbreviations
*A Pearson correlation coefficient (Pearson r) measures how strong the association is between 2 variables. It ranges from 1 (exactly correlated) to -1 (exactly inversely correlated).
†LVEF (%) are median values. Changes in LVEF are LS mean change values from baseline.
‡LS geometric mean concentration changes from baseline NT-proBNP to follow-up.
§Background medical treatment of study patients at baseline included a beta blocker in 757 patients (95.3%), an ACEi or ARB in 602 (75.8%), and an MRA in 281 (35.4%). Of those not taking ACEi/ARB at baseline, 6% were ACEi/ARB naive, and 18.1% had previously been on but were not currently on ACEi/ARB treatment.11
E/e’, filling pressure (early diastolic filling velocity/early diastolic mitral annular velocity); LAVI, left atrial volume index; LS, least-square; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; MRA, mineralocorticoid receptor antagonist.
For hospitalised patients, improve their hearts from the start with ENTRESTO ®
Abbreviations
*Readmission was defined as the first hospitalization after inpatient initiation of study drug.
†CV death and HF rehospitalization (8-week, double-blind, followed by 4-week, open-label period) events were adjudicated as defined or probable. A patient was only counted once.
ADHF, acute decompensated heart failure; ARR, absolute risk reduction.
ENTRESTO® NSS - UAE
ENTRESTO® NSS - UAE
References
Velazquez EJ, Morrow DA, DeVore AD, et al; for the PIONEER-HF Investigators. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539-548. DOI:10.1056/NEJMoa1812851
Januzzi JL Jr, Prescott MF, Butler J, et al; for the PROVE-HF Investigators. Association of change in N-terminal pro–b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. Published online September 2, 2019. DOI:10.1001/jama.2019.12821.
Zile MR, Clagget BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68(22):2425-2436. DOI:10.1016/ j.jacc.2016.09.931
Morrow DA, Velazquez EJ,DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HFtrial. Circ.2019;139(19):2285-2288.DOI:10.1161/ CIRCULATIONAHA.118.039331
Bettencourt P, AzevedoA, PimentaJ, et al. N-terminal–pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circ.2004;110(15):2168-2174. DOI:10.1161/01.CIR.0000144310.04433.BE